Global Advanced Wound Dressings Market Exhibit To Grow At A CAGR Rate Of 6.4%
Tommye Hope
LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads) on and off LinkedIn. Learn more in our Cookie Policy.
The Global Organ Preservation Industry is poised to reach a substantial valuation of US$455 million, exhibiting a robust compound annual growth rate of 6.4% By 2032. Organ preservation represents the vital practice of safeguarding healthy donor organs, ensuring their readiness for transplantation into recipients. Notably, Static Cold Storage (SCS), a cutting-edge technique, plays a pivotal role in halting the detrimental effects of toxic metabolites on the preservation of healthy tissues, thereby sustaining normal organ functionality post-transplantation.
Global Advanced Wound Dressings Market Exhibit to Grow at a CAGR Rate of 6.4%
Download Zip https://psfmi.com/2yLwIt
Because of the increasing number of organ failures caused by diabetes, cardiovascular diseases (CVDs), obesity, and other serious medical problems, static cold storage organ preservation treatments are becoming more common. Innovative and sophisticated organ preservation strategies, such as NMP, act as a growth-inducing agent.
In clinical and experimental research, such strategies help to reduce the risk of reperfusion damage after transplantation and improve static cold storage organ preservation results. Furthermore, an increasing number of government and non-government regulations and activities to encourage organ donation are positively impacting the growth of the organ preservation solutions market.
The growing number of people who volunteer to donate their organs for transplantation and research is also propelling the market forward. Other factors, such as increased R&D and significant developments in the global organ preservation industry, are expected to significantly contribute to market expansion.
The global active wound care market is expected to witness significant growth owing to the rising prevalence of ulcers. Moreover, the report predicts that ulcers may account for a significant share in terms of revenue in the global active wound care market. In the ulcer segment, diabetic foot ulcer is anticipated to gain traction as a considerable number of people contract the disease owing to the increasing prevalence of diabetes. In developing countries, foot ulcer is the one of the most common and feared complications associated with diabetes. This was found in a study published by the National Institute of Health (NIH). Also the study has revealed that around 15% of diabetic people in developing countries is likely to get diabetic foot sores or ulcers at some stage of their life. Ulcer healing is more complicated as it is vulnerable to infection and this is the reason the ulcer segment is expected to register a healthy growth rate by 2025.
From a geographical standpoint, North America is projected to offer impressive growth opportunities throughout the forecast period. This is mainly ascribable to the rising prevalence of wounds and diabetic population in North America. In addition to this, presence of sophisticated healthcare infrastructure leading to the rising demand for active wound care products and treatment, drives the active wound care market in this region. However, in the coming years the active wound care market in Asia Pacific is anticipated to show higher rate of growth on account of the high prevalence of unmet medical requirements in the region.
Rapid Lifestyle Changes and Rising Technological Advancements to Drive the Market. "Aged people are more prone to contract diseases such as venous leg ulcers which takes long healing time. Therefore, the adoption of active wound care treatment is expected to increase in response to the rising geriatric population in the forthcoming years," said a lead analyst at Fortune Business Insights. Increasing government support in terms of funding for research initiatives is another factor aiding the expansion of the active wound management. Also, several technological developments in active wound healing is likely to drive the active wound care market in the forecast years. For instance, MTF Biologics, with the help of technology, introduced a product called Amino Viable Band Membrane in 2018. The main objective of this product was to heal acute and active wounds. Enabled by this factor, other companies are also planning to expand their product portfolio, giving rise to active wound care technologies.
On the downside there are certain factors that may limit the global active wound care market to an extent. Unfavorable reimbursement policies on healthcare is one of the main factors impeding the growth of the active wound care market. Also, high cost associated with active wound care products and treatment is another factor that may hamper the growth of the active wound care market.
Increased focus of market players on R&D, combined with increasing per capita healthcare spending in emerging countries, and implementation of reimbursement policies for advanced wound care products are factors driving the growth of the global advanced wound dressings market.
The Hemostatic Agents Market in Asia Pacific is expected to grow at a relatively higher CAGR. Baxter (the leading organization in global market), plans to expand its operation in emerging nations such as India and China to enhance its accessibility.
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
A venous leg ulcer is a long-lasting chronic sore that usually develops on the inside of the leg, just above the ankle. It can develop after a minor injury, where persistently high pressure in the veins has damaged the skin. According to the NHS, venous leg ulcer is the most common type of leg ulcer, accounting for over 90% of all cases and it affects around 1 in 500 people in UK. The rise in prevalence of venous leg ulcers and the rise in the adoption of compression therapy for the treatment of venous leg ulcers are the key factors responsible for elevating the market growth during the forecast period. The rising awareness about the availability of treatment options for venous leg ulcers and growing advancements in the treatment procedures are anticipated to propel the VLU treatment market growth during the forecast period.
Venous leg ulcers are hard to heal. However, innovations in treatment options has been observed as a significant venous leg ulcer treatment market trend. Compression therapy has been clinically proven to accelerate VLU healing time and to decrease the recurrence rate. Along with this, robust research activities by key market players in compression therapy product developments is significantly increasing its adoption among the patients. For instance, in February 2018, SIGVARIS launched three inelastic compression products (COOLFLEX NF, COMPREFLEX REDUCE and COMPREFLEX ARM.) for the treatment of venous leg ulcer.
Globally, the prevalence of venous leg ulcers is increasing at a rapid pace. Immobility, varicose veins, obesity, pregnancy, previous deep vein thrombosis are some of the factors that contribute to the development of venous leg ulcers. According to an article published by The National Center for Biotechnology Information (NCBI) in 2010, the prevalence of venous leg ulcers in the U.S. is approximately 600,000 annually. This, coupled with rising awareness among the patient population regarding available treatment options, and rising geriatric population are poised to accelerate the market growth.
Lack of awareness about the treatment options for venous leg ulcers in many less-developed countries is likely to hinder venous leg ulcer treatment market growth. Moreover, the high cost of ulcer management is likely to restrict the market growth. However, initiatives by governmental and non-governmental organizations in enhancing the awareness about the availability of innovative treatment options in the market for venous leg ulcers and various product launches to expand product offerings by many key players are likely to offer valuable opportunities for expansion in emerging regions.
In terms of product, the market has been segmented into compression therapy, advanced wound dressings, and others. Among them, the compression therapy segment is anticipated to dominate the venous leg ulcer treatment market. Introduction of advanced compression bandages and stockings for the treatment of venous leg ulcers and increasing adoption of these products are some of the major factors to drive the compression therapy segment's growth. In combination to this, the growing awareness about the benefits of compression therapy among the patients is likely to increase the usage of compression therapy at an accelerated speed. Moreover, the segment is projected to continue its dominance by expanding at a significantly high growth rate throughout the forecast period.
The advanced wound dressings segment is expected to witness considerable growth rate, owing to the increased number of advanced wound dressing launches by the market players. For instance, In February 2019, AxioBiosolutions launched MaxioCel, the next generation chitosan-based advanced wound care dressing for the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, and other complex wounds.
7fc3f7cf58